Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Noninvasive fibrosis scores not sensitive in people with fatty liver disease and T2D

Key clinical point: Currently available noninvasive methods to detect advanced fibrosis do not work well in people with diabetes.

Major finding: Of four currently used scoring systems, sensitivity was between 17% and 64%, compared with liver biopsy.

Study details: A retrospective cohort study looking at biopsy, clinical and laboratory records for more than 1,100 patients with type 2 diabetes and nonalcoholic fatty liver disease over 15 years at one center.

Disclosures: Dr. Singh and colleagues reported no conflicts of interest or outside funding for their study.

Citation:

Singh A et al. J Clin Gastroenterol. 2020 Mar 11. doi: 10.1097/MCG.0000000000001339.